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Abstract
Background: Hand, foot and mouth disease is caused by Enterovirus 71 (EV-A71) and Coxsackieviruses. EV-A71
infection is associated with high fever, rashes and ulcers but more severe symptoms such as cardiopulmonary
failure and death have been reported. The lack of vaccines highlighted the urgency of developing preventive
agents against EV-A71. The molecular determinants of virulent phenotypes of EV-A71 is unclear. It remains to be
investigated if specific molecular determinants would affect the cell culture growth characteristics of the EV-A71
fatal strain in Rhabdomyosarcoma (RD) cells.
Results: In this study, several genetically modified sub-genotype B4 EV-A71 mutants were constructed by site-
directed mutations at positions 158, 475, 486, 487 and 5262 or through partial deletion of the 5′-NTR region (Δ
11 bp from nt 475 to 486) to generate a deletion mutant (PD). EV-A71 mutants 475 and PD caused minimal
cytopathic effects, produced lowest viral RNA copy number, viral particles as well as minimal amount of viral
protein (VP1) in RD cells when compared to mutants 158, 486, 487 and 5262.
Conclusions: The molecular determinants of virulent phenotypes of EV-A71 sub-genotype B4 strain 41 (5865/Sin/
000009) were found to differ from the C158 molecular determinant reported for the fatal EV-A71 sub-genotype B1 strain
(clinical isolate 237). The site-directed mutations (SDM) introduced at various sites of the cDNA affected growth of the
various mutants when compared to the wild type. Lowest viral RNA copy number, minimal number of plaques formed,
higher infectious doses required for 50% lethality of RD cells and much reduced VP1 of the EV-A71 sub-genotype B4
strain 41 genome was attained in mutants carrying SDM at position 475 and through partial deletion of 11 bp at the
5′-NTR region.
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Background
The World Health Organization (WHO) and the scientific
community have been addressing challenges unprece-
dented in public health posed by Enteroviruses in the
post-poliovirus era. Enteroviruses such as Enterovirus 71
(EV-A71), Coxsackie type A16 (CV-A16) and other
enteroviruses causing hand, foot and mouth disease
(HFMD) have led to over 7 million infections, including
2457 fatalities in China from 2008 to 2012 [1]. However,
due to increasing travels and rapid globalization,
outbreaks in other parts of the world have also appeared
in cyclical epidemics [2, 3].
Within the family Picornaviridae, the genus Enterovirus
comprises 12 species. The species Enterovirus A consists
of 25 serotypes and includes the enteroviruses that can
cause HFMD such as EV-A71, CV-A16, CV-A5, CV-A6,
CV-A8 and CV-A10 [4]. Five years of virological surveil-
lance in China (2008–2014) showed that 43.73, 22.04, and
34.22% of HFMD cases were due to EV-A71, CV-A16 and
other enteroviruses, respectively [5]. However, Coxsackie
viruses which are common etiological agents of HMFD do
not generally cause neurological or cardiopulmonary dis-
ease but EV-A71 is the main causative agent of fatal
HFMD infections [6]. Mild symptoms of EV-A71 infection
in children range from fever (≥39 °C), sore throat, loss of
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appetite and rash with vesicles on the hands and feet. EV-
A71 constituted 80–85% of the pathogens isolated from
HFMD-related deaths based on clinical etiological data
[7]. The lack of vaccines and antiviral drugs against EV-
A71 highlights the urgency and significance of developing
preventive and treatment agents against EV-A71.
The EV-A71 virus is classified as Human enterovirus A
(HEV-A) species, belonging to the genus Enterovirus in
the family Picornaviridae [4, 8]. Phylogenetic analysis sug-
gests that EV-A71 and CV-A16 were genetically highly
related and the common ancestor of EV-A71 is likely to
have emerged around 1941 [9]. The EV-A71 virus is a
non-enveloped icosahedral viral particle that contains a
single-stranded, positive sense, poly-adenylated viral Ribo-
nucleic Acid (RNA) of approximately 7.4 kb. The capsid is
made up of 60 protomers, each consisting of 4 polypep-
tides that comprise the structural proteins, VP1, VP2, VP3
and VP4. Of all the polypeptides, VP4 is located on the
internal side of the capsid while VP1, VP2 and VP3 are
located on the external surface of the EV-A71 virus [10].
The EV-A71 genome comprises a 5′ non-translated
region (5′-NTR), a long open reading frame (ORF) and a
short 3′-NTR followed by a poly-adenylated (poly A) tail.
The 5′-NTR contains an internal ribosome entry site
(IRES) which allows viral protein translation in a cap-
independent manner [11]. The ORF is translated into a
single large polyprotein of approximately 2100 amino
acids (aa) which is divided into three regions (P1-P3). The
polyprotein undergoes a series of processing events, cul-
minating in the maturation cleavage of the polyprotein
which generates structural and non-structural viral pro-
teins [12]. The four structural proteins, VP1, VP2, VP3
and VP4, are encoded by the P1 region which constitutes
the virus capsid. Proteins derived from the non-structural
P2 (2Apro, 2B, 2BC, 2CATPase) and P3 (3A, 3AB, 3B, 3Cpro,
3CDpro, 3Dpol) regions are mostly directly involved in viral
replication and structural and biochemical changes which
are observed within the infected cell [13]. Non-structural
proteins (2A and 3C proteinases) are responsible for apop-
tosis of infected cells in vitro [14, 15].
Identification of molecular determinants in EV-A71 by
comparing genome differences have been reported. Li et
al. [16] evaluated the sequences of virulent and non-
virulent strains and concluded that four amino acids in
the capsid protein VP1 (GlyP710/Gln P710/Arg P710/Glu
P729), Lys P930 in protease 2A and four nucleotides in the
5′-NTR region (GP272, UP488 and AP700/UP700) are likely
to contribute to the EV-A71 virulent phenotype. The
variation of amino acids/nts. at these positions may
influence the EV-A71 viral RNA translation efficiency or
the enzymatic activity of proteases. Arita et al. [17]
isolated an EV-A71 (S1-3′) mutant derived from the EV-
A71 genotype A BrCr strain by introducing mutations in
the 5′-NTR region (A485G), 3D polymerase (TyrP73,
CysP363) and in the 3′-NTR (A7409G) of the EV-A71
genome. However, the virus still caused tremors in 3 cy-
nomolgus monkeys and was isolated only from the
spinal cord, indicating that a cooperative effect of the
mutations introduced had reduced neuro-virulence of
EV-A71 [17, 18].
Yeh et al. [19] constructed a series of infectious clones
containing chimeric 5′-NTR regions and mapped a gen-
etic determinant of EV-A71 virulence to nt. 158 within a
fragment comprising 12 nucleotides in the stem loop
(SL) II structure of EV-A71 clinical isolate 237. A single
nucleotide change from cytosine to uridine at position
158 (USLIIM-C158U) caused an alteration in the RNA
secondary structure of SL II which led to reduced viral
translation and virulence in mice. Mice infected with the
USLIIM-C158U mutant was observed to have prolonged
average survival time and survival rate as compared with
infection with the wild-type USLIIM (40% vs. 0%, P <
0.005) [19]. In this study, we are investigating if the EV-
A71 sub-genotype B4, strain 41 (5865/Sin/000009) has
the same or a different virulence determinant from sub-
genotype B1 (clinical isolate 237) and the BrCr prototype
strain [17]. The EV-A71 sub-genotype B4 virus (acces-
sion number: AF316321) was modified to carry a single
mutation at nucleotide position 158 by site-directed mu-
tagenesis to assess if the nucleotide is a common viru-
lence determinant between EV-A71 sub-genotypes B4
and B1.
In addition, we genetically modified the EV-A71 sub-
genotype B4 virus by substituting a single nucleotide at
either position 475, 486, or 487 based on the fact that
the corresponding nucleotides are responsible for the
neuro-virulence of Poliovirus Sabin strains 1, 2 and 3,
respectively as well as the EV-A71 BrCr prototype strain.
Figure 1 illustrates the predicted RNA secondary struc-
ture of EV-A71 strain 41 from nt. 474 to 541. There
is only a single nucleotide difference between the fatal
(GenBank: AF316321) and the non-fatal strain
(GenBank: AF352027) isolated from the Singapore
outbreak in 2000 based on comparative sequence
analysis [20]. The single nt difference at position 5262
in the 3A non-structural region could be the molecu-
lar determinant of virulence in the EV-A71 genome.
The growth characteristics of the various mutated EV-
A71 strains were evaluated in Rhabdomyosarcoma (RD)
cell culture by plaque forming ability, viral infectivity by
tissue culture infectious dose (TCID50) determinations,
RNA copy number and the quantification of VP1
formed.
Results
Cytopathic effects (CPE) caused by mutants
The EV-A71 sub-genotype B4 virus (accession number:
AF316321) was genetically modified to carry a single
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mutation at nucleotide position 158 by site-directed mu-
tagenesis to assess if the nucleotide is a common viru-
lence determinant between EV-A71 sub-genotypes B4
and B1. The effect of this change was evaluated by quali-
tative growth assays such as cytopathic effects (CPE) in
Rhabdomyosarcoma (RD) cells. Mutant EV-A71 158
(A158T) virus showed minimal CPE when transfected
into RD cells with a multiplicity of infection (MOI) of
0.1 (Fig. 2a) as compared to the positive control (EV-
A71 wild type strain 41) (Fig. 2h). CPE was seen as
round and shrunken cells which floated on the surface
and there was extensive CPE seen with the EV-A71 wild
type strain 41. All experiments were repeated at least
three times on separate days.
The virulence determinants of wild type Poliovirus
and EV-A71 genotype A BrCr prototype strain reported
in previous studies served as references in this study to
produce EV-A71 mutants that have reduced virulence in
cell cultures. The EV-A71 strain 41 virus was also genet-
ically modified by substituting nucleotides at position
475, 486, or 487 as the corresponding nucleotides were
reported to be responsible for neuro-virulence of Polio-
virus serotypes 1, 2 and 3, respectively. The mutant EV-
A71 475 (C475T) caused the lowest CPE in RD cells
Fig. 1 Predicted RNA secondary structure of EV-A71 strain 41 from nt. 474 to 541. Due to slight differences in the length of the 5′-NTR, nt. 480 in Sabin
1 is at the equivalent position 486 in this figure. Nt. 481 in Sabin 2 is at the equivalent position 487, and nt. 472 in Sabin 3 is at the equivalent position
475 of the EV-A71 genome
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(Fig. 2b) when compared to mutants 486 (A486G)
(Fig. 2c) and 487 (G487A) (Fig. 2d). Out of the three
mutants, A486G caused the highest amount of CPE
(Fig. 2c) in RD cells as evident from the rounding and
shrunken nature of numerous cells. EV-A71 mutant 487
(G487A) displayed intermediate CPE when transfected
into RD cells with a MOI of 0.1 (Fig. 2d).
Analysis of the genomic sequences of two EV-A71
strains, one isolated from a non-fatal case and another iso-
lated from a fatal case shows that a single nucleotide (nt)
difference between the fatal strain (EV-A71 strain 5865/
Sin/000009, designated as strain 41), and the non-fatal
strain (EV-A71 strain 5666/Sin/002209, designated as
strain 10) might be responsible for virulence in the fatal
strain. This is based on a previous observation by Singh et
al. [20] where they indicated the difference between the
fatal and non-fatal strain is at nucleotide (nt) position
5262. In the current investigation, the Adenine residue at
position 5262 present in the fatal strain (strain 41) was
changed to the Guanine residue. Based on the morphology
shown in Fig. 2e, infection of RD cells by mutant A5262G
showed no CPE as cells were relatively healthy when com-
pared to the extensive lysis observed with the positive wild
type control (Fig. 2h). There was hardly any floating cells
observed and this is similar to no CPE being observed with
the negative control (without virus) (Fig. 2g).
An EV-A71 mutant that carried a partial deletion in
the 5′-NTR region in the viral genome was also con-
structed. This was carried out to reduce the efficiency of
viral replication as a deletion in this 5′-NTR region was
found to generate genetically stable Poliovirus [21]. In
this study, deletion was created from nt. positions 475 to
485 (Δ11). The mutant EV-A71 PD (Partial Deletant 5′-
NTR) did not show any CPE (Fig. 2f ) and the micro-
scopic image showed similarity with the image taken
from the uninfected RD cells that acted as a negative
control (Fig. 2g). These microscopic images are in direct
contrast to the extensive CPE observed for the EV-A71
wild type strain 41 (Fig. 2h).
Quantification of viral RNA copy number
Observation of CPE in Rhabdomyosarcoma (RD) cells is a
qualitative indication of the extent of infectivity of the
various mutants in comparison with the EV-A71 wild type
strain 41. Approaches such as determination of the viral
RNA copy number, plaque forming units (PFU), 50%
Fig. 2 Cytopathic effects (CPE) caused by mutants a EV-A71 (A158T) b C475T c A486G d G487A e A5262G and f PD (Partial Deletant, 5′-NTR) in
Rhabdomyosarcoma (RD) cells in comparison with g uninfected RD cells (negative control using Opti-MEM) and h EV-A71 wild type strain 41
infected RD cells (positive control). Transfection of infectious RNA into RD cells was performed with the use of Lipofectamine 2000 reagent using
EV-A71 mutants at a MOI of 0.1. CPE was seen as round and shrunken cells that eventually dislodged from the surface. Magnification used (X 100)
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tissue culture infectious doses (TCID50) and amount of
viral capsid protein 1 (VP1) present in each strain will en-
able a better quantitative comparison of the growth char-
acteristics of the various mutant strains. The viral RNA
copy number of the various EV-A71 mutant strains was
evaluated after growing in Rhabdomyosarcoma (RD) cell
culture.
The wild type EV-A71 strain 41 gave the highest yield
of viral RNA copy number (5.2 × 103) in RD cells. As for
EV-A71 mutants 475 and PD, very low RNA copy num-
bers were detected for both mutants at 1.02 × 102 and
1.05 × 102, respectively (Fig. 3). There are a few posi-
tions that appear to reduce the replication of the virus
when the mutated strains were evaluated in vitro (Fig. 3).
For example, EV-A71 mutant 158 (A158T) mutated at
position 158 gave a yield of 2.0 × 103 RNA copy number
which is less than half that of the wild type RNA copy
number (5.2 × 103). Amongst all the mutants being eval-
uated, mutant 486 (A486G) carrying SDM at position
486 expressed the highest viral RNA copy number of
4.2 × 103 when compared to the wild type strain 41. The
mutant 487 (G487A) carrying SDM at position 487
produced a viral RNA copy number of 2.0 × 102. The
mutant 5262 (A5262G) with a SDM at position 5262
also showed much reduced viral RNA copy number of
7.0 × 102 (Fig. 3).
The mutation introduced at position 5262 did consid-
erably reduce the viral RNA copy number to 10-fold less
when compared to the wild type copy number. There-
fore, mutant 5262 will need to be further evaluated by
plaque forming ability, TCID50 and the amount of VP1
formed.
Infectivity of mutant viruses quantified by tissue culture
infectious dose (TCID50)
The tissue culture infectious dose (TCID50) for the EV-
A71 wild type strain 41 and mutant viruses were quantita-
tively determined. TCID50 refers to the quantity of virus
that produced a cytopathic effect in 50% of the cultures
inoculated. The EV-A71 mutant 158 (A158T) at position
158 demonstrated a higher TCID50 of 1.00 × 10
4 when
compared with the positive control EV-A71 wild type
strain 41 (TCID50 of 1.00 × 10
3) (Table 1). This indicates
that EV-A71 mutant 158 would require a higher quantity
of virus (approximately 10 times more) to produce a cyto-
pathic effect in 50% of the cultures inoculated.
In addition, the mutant carrying SDM at position 486
(A486G) also had 10 times increased TCID50 value
(1.00 × 104) when compared with the positive control
EV-A71wild type strain 41, suggesting that the mutant
had decreased infectivity. Both mutants 5262 and mu-
tant 487 showed more than 100-fold increase in TCID50
value when compared against the EV-A71 wild type
strain 41. Mutant 475 with SDM at position 475 and
mutant PD both showed a significant 1000 fold increase
in TCID50 to 1.00 × 10
6 (Table 1). Analysis of the TCID50
values indicates that mutant 475 and the partial deletant
(PD) required much higher doses of viruses to cause cy-
topathic effects in 50% of the tissue cultures.
Fig. 3 Quantification of Viral RNA Copy Number. Transfection of infectious RNA into RD cells was performed with the use of Lipofectamine 2000
reagent and EV-A71 mutants at a MOI of 0.1. The viral RNA copy number was determined at 24 h post-infection by TaqMan Real-Time PCR. Viral
RNA copy numbers are the average of three biological replicates. Error bars represent the standard deviation of the mean
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Quantification of virus by the plaque assay
The ability of various EV-A71 mutant strains to form
plaques was evaluated in Rhabdomyosarcoma (RD) cell
culture (Fig. 4). The wild type EV-A71 strain 41 pro-
duced the highest number of plaques (5.0 × 107 PFU/
mL) in RD cells. The least number of viral plaques were
formed by mutant 475 carrying a site directed mutation
(SDM) at position 475 (7.0 × 104 PFU/mL) and the par-
tial deletant (PD) carrying a 11 bp deletion in the 5′-
NTR (9.0 × 104 PFU/mL) (Fig. 5). From analysis of the
data presented in Fig. 5, there are a few positions in the
viral genome that are likely to reduce the ability of the
virus to replicate and form plaques. The EV-A71 mutant
158 (SDM at position 158) gave a yield of 2.0 × 105 PFU/
ml and the mutant 486 carrying SDM at position 486
also had reduced plaque number (3.5 × 105 PFU/ml)
when compared to the positive control (EV-A71 wild
type strain 41), albeit at a much higher copy number
than the mutant 487 carrying SDM at position 487
(1.0 × 105 PFU/mL).
The mutant 5262 with a SDM at position 5262 also
showed much reduced plaque number (1.8 × 105 PFU/
mL). As the ability to form plaques is reduced for certain
mutant strains, viral growth is expected to be lower.
This would mean that viraemia caused by a lower num-
ber of viruses will be milder as the viral load would
affect virulence of the virus.
Production of VP1 by mutant strains
The ability of the various mutated EV-A71 strains to
produce viral particles could be evaluated by detection
of VP1 by immunoblotting with the monoclonal anti-
body directed at VP1. Supernatant derived from trans-
fected RD cells was processed and subjected to
electrophoresis to separate the EV-A71 total proteins.
The amount of VP1 present in each mutant was assessed
by Western blot analysis. A single band was observed at
an approximate molecular weight (MW) of 32 kDa
(Fig. 6). This band corresponds to the VP1 monomer
with an apparent MW of 32.7 kDa.
RD cells infected with the wild type EV-A71 strain 41
(Lane 7) demonstrated the largest amount of VP1 pro-
tein (32.7 kDa) being detected in the Western blot ana-
lysis. Minimal amount of VP1 was detected in the
mutant strain 475 carrying the site specific mutation at
position 475 (Lane 2) and the partial deletant (PD) in
the 5′-NTR (Lane 6) (Fig. 6). This was consistent with
Table 1 Tissue Culture Infectious Dose50 (TCID50) of EV-A71
mutants in comparison with the wild type EV-A71 strain 41
EV-A71 Mutants TCID50
A158T 1.00 × 104
C475T 1.00 × 106
A486G 1.00 × 104
G487A 7.50 × 105
A5262G 3.41 × 105
Partial Deletant (PD) 5′-NTR 1.00 × 106
Positive Control (EV-A71 strain 41) 1.00 × 103
RD cells were infected with the EV-A71 wild type and mutant viruses at a MOI
of 0.1. The TCID50/ml values are calculated using the Reed and Muench
formula determined from two independent experiments [26]
Fig. 4 Quantification of plaque forming units by EV-A71 mutants 158, 475, 486, 487, 5262, partial deletant (PD) and the wild type EV-A71 strain
41. The negative control represents uninfected RD cells. EV-A71 mutants were transfected at a MOI of 0.1. The plaque assays were performed on
monolayer RD cells incubated at 37 °C and were repeated at least two separate times
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results from plaque numbers, TCID50 infectious dose,
and RNA copy numbers. There are a few nucleotide (nt)
positions in the viral genome that are likely to reduce
the infectivity of the virus in RD cells as we observed
the amount of viral capsid VP1 being formed was much
lesser in some mutants than the amount of VP1 being
formed by the wild type strain 41. For example, EV-A71
mutant 158 at position 158 (Lane 1) and mutant 5262
(Lane 5) showed reduced amounts of viral VP1 protein
when compared to the wild type EV-A71 (Lane 7)
(Fig. 6).
Discussion
The molecular basis of virulence in EV-A71 is still
uncertain. Arita et al. [17] isolated an EV-A71 mutant
(S1-3′) carrying mutations in the 5′-NTR region
(A485G), 3D polymerase (Tyr-73, Cys-363) and in the
3′-NTR (A7409G) region in the EV-A71 genotype A
genome. Although the virulence of the mutant (S1-3′)
was significantly reduced, it was still able to cause
tremors in cynomolgus monkeys [17]. In addition,
Yeh et al. [19] reported that the virulence determin-
ant in an EV-A71 sub-genotype B1 (clinical isolate
237) was due to the presence of cytosine at position
158. This mutation was observed to decrease the
virulence of EV-A71 sub-genotype B1 strain [19]. This
study demonstrated that the mutation at 158 did reduce
viral infectivity by expressing less than half the viral
RNA copy number when compared to the wild type but
the reduction of infectivity was significantly lower than
that observed in EV-A71 mutants 5262, 487, 475 and
the partial deletant, PD. Hence, the results show that
EV-A71 sub-genotype B4 has a molecular determinant
of cell culture growth phenotype which is different from
the molecular determinants present in the sub-genotype
B1 strain.
In this study, we genetically modified the EV-A71 sub-
genotype B4, strain 41 (5865/Sin/000009) by substituting
nucleotides at positions 475, 486, and 487 based on the
fact that these nucleotides were responsible for the
Fig. 5 Plaque Forming Units by EV-A71 mutants and the wild type EV-A71 strain 41. RD cells were transfected with EV-A71 mutants and the wild type
EV-A71 strain 41 at a MOI of 0.1. Plaque formation was observed 72 h post-infection. PFU numbers are the average of two biological replicates; Error
bars represent the standard deviation of the mean
Fig. 6 Western blot analysis of VP1 formed by the various EV-A71 mutants. The amount of EV-A71 VP1 protein and β-actin loaded in each lane was 5 μg.
The lanes are labelled as follows: lane 1, EV-A71 Mutant 158; lane 2, EV-A71 Mutant 475; lane 3, EV-A71 Mutant 486; lane 4, EV-A71 Mutant 487;
lane 5, EV-A71 Mutant 5262; lane 6, EV-A71 Mutant Partial Deletant (PD) 5′-NTR; lane 7, Positive control (EV-A71 Virus); lane 8, Negative control
(uninfected RD cells). The molecular weight of the EV-A71 VP1 protein is estimated to be 32.7 kDa with reference to molecular weight markers
(from 10–250 kDa) (data not shown)
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neurovirulence of poliovirus Sabin strains 1, 2 and 3,
respectively. From the analysis of nucleotide (nt) sequences
present in the three poliovirus Sabin strains, nt. substitu-
tions which were critical in attenuating mutations in the
virulent strains isolated from the cerebrospinal fluid were
identified. There were 57 nt. substitutions distinguishing
the Sabin 1 strain from its parent wild type strain [22].
Among these nt. substitutions, the A480G in the IRES is
the most important determinant of the attenuated pheno-
type of Sabin 1. Their study strongly suggested that nt. 480
influences the formation of a highly ordered structure in
the 5′-NTR that is responsible for neuro-virulence [23].
Four other nt. substitutions contributing to the attenuated
phenotype were mapped to the capsid region. In addition,
there was also one substitution that contributed to the
temperature-sensitive phenotype mapped to the 3DPol
region [24].
However, there were only 2 nt. substitutions found in
the Sabin 2 strain that appeared at position 481 within
the IRES region and at position 2909 within the VP1.
For Sabin 3, a total of 10 nt. substitutions were found to
differ from its parent strain, but only 3 substitutions
appeared to be the main determinants for the attenuated
phenotype (C274U in IRES, C2034U in VP3, and
U2493C in VP1) [25]. Sabin 3 strain was also found to
be the most genetically unstable of the three Sabin
strains. As a result of the analysis of the molecular deter-
minants of cell culture growth, in vitro construction of
polioviruses with reduced-virulence could be performed
via the introduction of mutations in the 5′-NTR to
reduce the efficiency of viral replication. The EV-A71
strains had 46% amino acid identity with the polioviral
P1 capsid region and 55% with the entire polyprotein. In
addition, EV-A71 and PV share high sequence homology
especially in the 5′-NTR region [22]. For example, EV-
A71 carried the same C nt. at position 475 which corre-
sponds to position 472 in the PV genome.
Li et al. [16] found that there were nine amino acid
substitutions (H22Q, P27S, N31S/D, E98K, E145G/Q,
D164E, T240A/S, V249I, A289T) that were detected
after aligning the VP1 sequences of fatal and mild EV-
A71 strains of sub-genotype C4. As such, these residues
may be potential virulence determinants in VP1 and
could convert mild EV-A71 strains into fatal strains. The
study was consistent with previous investigations by
Chang et al. [26] who observed that the E145Q substitu-
tion at the 5′-NTR was a common difference in the EV-
A71 genome isolated from mild and fatal cases of
HFMD. Additionally, they also discovered that strains
isolated from patients with fatal outcomes had greater
substitutions in the 5′-NTR and the IRES regions [26].
This is to be expected as the 5′-NTR was responsible
for cap-independent translation of viral proteins. The
position of a certain specific amino acid in the genome
may have a profound significance on virulence [27]. For
example, it was reported that the presence of Asn at
position 165 of VP2 in the Coxsackievirus B3 was
responsible for a cardiovirulent phenotype [28] or viru-
lence could be due to the cooperative effect of several
critical amino acids.
The virulence determinants of Poliovirus and EV-A71
reported in previous studies served as references in this
study to produce EV-A71 viruses that are have reduced
virulence in cell cultures. An EV-A71 mutant bearing a
long deletion in the 5′-NTR of the genome was con-
structed. In addition, the single nt. difference between
the fatal (strain 41) and non-fatal strain (strain 10) of
EV-A71 (sub-genotype B4) was examined for virulence
by changing the nt. substitution at position 5262 in the
EV-A71 viral genome [20]. The mutant 5262 did not
completely eliminate the ability to replicate and form
plaques. There was some reduction in viral replication
by SDM at this site but the effect was less than the
effects brought about by introducing SDM into sites
475, 487 and the partial deletion created in the 5′-NTR
region. Analysis of the TCID50 values indicated that mu-
tants 475 and the PD strain required higher doses of
virus to cause cytopathic effects in 50% of the tissue cul-
ture. This was consistent with the fact that both mutants
have lower infectivity in RD cells than mutants 158, 486,
487, and 5262.
The ability to form plaques was observed to have been
reduced for some of the mutants. The virulence of the
mutants could be indicated by plaque forming units/ml
(PFU/ml). Consistent with the TCID50 values, the least
number of viral plaques was formed by the mutant car-
rying SDM at position 475 (7.0 × 104 PFU/mL) and the
partial deletant (PD) (9.0 × 104 PFU/mL). The lower
PFU/ml indicates that viral growth was slower for these
2 mutants. In addition, RD cells infected with the wild
type EV-A71 strain 41 demonstrated the largest amount
of the VP1 protein being produced as evident from a
thick, single band with molecular weight (MW) of
32 kDa. This band corresponds to the VP1 monomer
with an apparent MW of 32.7 kDa. Small amounts of
VP1 were produced by mutants 487 and 5262. Mutants
158 and 486 were found to still produce significant
amounts of VP1. Minimal amounts of VP1 were
detected in the mutant strain carrying the site specific
mutation at position 475 and the partial deletant (PD) in
the 5′-NTR. The analysis of VP1 indicates that SDM at
position 475 and deletion of 11 bp in the 5′-NTR were
responsible for significant reduction of infectivity in
these 2 strains, respectively.
RD cells infected with the wild type EV-A71 strain 41
gave the highest yield of viral RNA copy number (4.6 ×
103). As for EV-A71 mutants 475 and PD, minimal RNA
copy number was detected for both mutants at 1.02 ×
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102 and 1.05 × 102 viral RNA, respectively. This was con-
sistent with the minimal number of plaques being
formed, higher infectious doses required for 50% lethal-
ity of RD cells and much reduced VP1 being observed.
Amongst all the mutants being evaluated, mutant 486
carrying SDM at position 486 (A486G) expressed the
highest viral RNA copy number of 4.2 × 103 when com-
pared to the wild type strain 41.
Conclusions
Mutant 158 was found not to have the most reduction
in infectivity of RD cells in vitro as it still produced
more RNA, viral particles and VP1 than mutants 5262,
487, 475 and PD, it can be inferred that it is not the sin-
gle virulence determinant for strain 41 which belongs to
the sub-genotype B4. This is in contrast to the findings
by Yeh et al. [19] who established that the molecular de-
terminant C158 was responsible for molecular virulence
in the sub-genotype B1. The single site mutation created
by introducing a nt. change at position 5262 did not
completely eliminate the ability to replicate and form
plaques in RD cells. There was some reduction of viral
growth by SDM at this site but the effect was less than
the effects brought about by introducing SDM into
either sites 475, 487 or the partial deletion created in the
5′-NTR region.
The data reported in this investigation shows that a
partial deletion created in the 5′-NTR and SDM at nt.
475 maybe potential molecular determinants of cell
culture growth characteristics of EV-A71 in RD cells.
Further studies should be conducted to investigate the
stability of each of the mutation that was created and to
further explore the role of early (virus attachment) and
late events (virus assembly, release) in the pathogenesis
and expression of the growth phenotype of EV-A71.
Methods
Cell culture
Human Rhabdomyosarcoma cells (RD, ATCC # CCL-
136) were cultured in Dulbecco’s modified Eagle’s min-
imal medium/F-12 (DMEM/F-12, Invitrogen, USA),
supplemented with 10% foetal bovine serum (FBS) (Gibco,
USA), 1% penicillin/streptomycin, 1% L-glutamine and 1%
essential amino acids. The cell line was grown at 37 °C in
5% CO2 until 80–90% confluency.
Viral infection
RD cell monolayers in 75-cm2 flasks were inoculated
with 100 μL EV-A71 strain 5865/Sin/000009 (GenBank
accession number AF316321). Infected cells were incu-
bated with 1 mL DMEM containing antibiotics but no
serum at 37 °C until complete cytopathic effect (CPE)
was apparent. RD cells were frozen at −80 °C and
thawed, three times, and cell debris was removed by
centrifugation at 14,000 x g for 10 min at 4 °C. Superna-
tants were used for harvesting the virus.
RNA extraction and reverse transcription
Viral RNA was extracted from EV-A71 using the
QIAmp® Viral RNA Mini Spin Kit (Qiagen, Calif., USA).
The kit was used according to the manufacturer’s
instructions. The purified RNA was reverse transcribed
into cDNA by using the SuperScript® III First Strand
Synthesis SuperMix Kit (Invitrogen, Calif., USA). Each
cDNA synthesis mixture contained 10X annealing buffer,
25 mM MgCl2, 0.1 M oligo(dT), RNAseOUT/Super-
script III RT and viral RNA as template.
Cloning of EV-A71 cDNA into the pCR-XL-TOPO vector
Full length cDNA of EV-A71 was amplified using poly-
merase chain reaction (PCR). Each PCR reaction
contained 5X Phusion HF buffer, 10 mM dNTP, 0.1 g of
each primer, 1 μg template cDNA and Phusion HSII
DNA Polymerase. The following cycling conditions were
employed for the PCR reactions: 98 °C for 30s, followed
by 98 °C for 10s, 64 °C for 30s and 72 °C for 5 min for
30 cycles. The cycles were terminated with a 30s exten-
sion at 68 °C. The amplified cDNA was cloned into the
pCR®-XL-TOPO® vector (Invitrogen, Calif., USA).
Approximately 100 ng of the full length EV-A71 cDNA
was ligated to 1 μL pCR®-XL-TOPO® vector according to
the manufacturer’s protocol in the TOPO® XL PCR
Cloning Kit (Invitrogen, Calif., USA). The ligation mix-
ture was incubated for 5 min at room temperature, then
1 μl of the 6x TOPO® Cloning stop solution was added
and the tubes were placed on ice. The recombinant EV-
A71 pCR®-XL-TOPO® vector was stored at −20 °C for
further downstream processes.
Site-directed mutagenesis
The EV-A71 full genome in the pCR®-XL-TOPO® plas-
mid acted as the substrate for single mutations using
designed primers and the QuickChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies, Calif.,
USA). EV-A71 mutants were constructed by introducing
site-directed mutations at nucleotide positions 158, 475,
486, 487, in the 5′-NTR and at position 5262 of the viral
genome, respectively. In the 1st stage of the reaction,
PCR was carried out. The mixture contained 10x reac-
tion buffer, 100 ng/μl of each primer, 100 ng ds DNA
template, 1 μL dNTP mix and 1 μL QuikChange
Lightning Enzyme mix. The PCR mixture was added up
to a total reaction volume of 50 μl. The PCR conditions
were set up at 95 °C for 2min.
In the 2nd stage of mutagenesis, 2 μl of the DpnI
restriction enzyme was added to the amplification prod-
uct to digest the methylated and hemi-methylated
parental DNA. The ligation mixture was incubated for
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5min at 37 °C. In the 3rd stage, transformation was per-
formed using XL 10-Gold® Ultracompetent cells (Agilent
Technologies, Calif., USA). The ligated mixture (2 μl)
was added to the competent cells and incubated on ice
for 30min. The cells were then subjected to heat shock
at 42 °C for 30s, and immediately placed on ice for
2min. An aliquot of the NZY+ broth (500 μl) was added
to the XL 10-Gold competent cell suspension, followed
by shaking of the transformed bacterial cells at 37 °C for
1 h. After the 1 h incubation, tubes were centrifuged at
13,000 × g for 1min. Clear supernatant was discarded
and the cell pellet was resuspended in 500 ul of fresh
NZY+medium and an aliquot of 0.2 ml was plated on
LB agar supplemented with 25 μg/ml kanamycin
sulphate (Invitrogen, Calif., USA). The E.coli cells were
incubated overnight for 16 h at 37 °C. Nucleotide sub-
stitutions were confirmed by DNA sequence analysis
using nucleotide Basic Local Alignment Software
(BLAST by NCIB).
Partial-deletion in the 5′-NTR of EV-A71 genome
EV-A71 with a partial deletion from nucleotide positions
475 to 485 in the 5′-NTR was constructed using two
designed primers that were 24 nucleotides in length
[namely EV-UTR-F(Δ11) and EV-UTR-R(Δ11)] and the
Q5® Site-Directed Mutagenesis Kit (New England Bio-
labs, USA) . The EV-A71 deletion mutant was confirmed
by DNA sequence analysis by nucleotide Basic Local
Alignment Software (BLAST by NCIB). Bacterial col-
onies that carried the viral genome with the correct
mutations were kept in 20% glycerol stock at −80 °C for
long term storage.
Restriction endonuclease digestion of plasmid DNA
Plasmid DNA (1–5 μg) purified from E.coli transfor-
mants was digested with EagI (New England BioLabs,
Massachusetts, USA). The reaction was incubated at
37 °C in a water bath for 2 h. Screening of DNA frag-
ments after digestion of the recombinant pCR-XL-
TOPO EV-A71 plasmid was carried out using DNA
agarose gel electrophoresis. The agarose gel was pre-
stained with GelRed nucleic acid stain (Biotium,
USA) prepared in 0.5X TAE buffer. DNA products
were mixed with gel loading buffer and loaded into
wells in the agarose gel. Electrophoresis was carried
out using 80 V and DNA bands were illuminated
with UV light. The size of the DNA fragments were
compared with a GeneRuler 1 kbp DNA ladder
(Invitrogen, USA).
Phenol-chloroform purification and ethanol precipitation
of DNA
The DNA solution was mixed with an equal volume of
phenol-chloroform (Invitrogen, Calif., USA) and vortexed
for 1min. The mixture was centrifuged at 15,000 × g for
10min to separate the aqueous and solvent phases. The
desired aqueous layer was carefully removed and mixed
with an equal volume of phenol-chloroform (1:1) (Invitro-
gen, Calif., USA) and vortexed for 1min. The mixture was
again centrifuged at 15,000 × g for 10min. The aqueous
layer was removed and 1/10 volume of chilled 3 M
sodium acetate (pH 5.2) and 1/10 volume of isopropanol
were added to the DNA sample and mixed well by invert-
ing the tube multiple times. Then, the sample was incu-
bated at −20 °C for 2 h to precipitate the DNA. The DNA
was pelleted by centrifugation at 15,000 × g for 30min at
4 °C. The supernatant was carefully removed and 1 ml of
cold 70% ethanol was added to wash off the remaining
salts. The DNA pellet was allowed to air dry for 5min with
the lid opened. The desired amount of TE buffer was
added into the tube in order to dissolve the DNA
Production of infectious EV-A71 RNA from cloned cDNA
RNA transcription was carried out using RiboMAX™
Large Scale RNA Production System-SP6 (Promega,
Calif., USA). The reaction was set up in 20 μl of reaction
volume by following the recommended protocol. The re-
action mixture was subjected to incubation at 37 °C for
4 h and followed by DNase treatment for 30min. The
DNase (Promega, Calif., USA) was added to the in vitro
transcription reaction at a final concentration of 1 U per
μg of DNA template. The Linear Control DNA supplied
by RiboMAX™ Large Scale RNA Production System-SP6
was used as a template for the production of RNA tran-
scripts of approximately 1.8 kb in length and served as a
positive control for the in vitro transcription reaction.
The in vitro transcribed EV-A71 RNA was visualized by
agarose gel electrophoresis prior to being used in trans-
fection of RD cells [29].
Transfection of RD cells with in vitro RNA transcripts
RD cells were seeded in a 24-well plate and incubated
for 24 h. When the cell confluence reached about 90%,
transfection of the RNA transcripts was performed with
the use of the Lipofectamine 2000 reagent (Invitrogen,
Calif., USA). The transfection reagent was washed away
4 h after transfection and cells were then cultured in
fresh medium containing 10% foetal bovine serum. Once
cytopathic effects (CPE) were observed (round and
shrunken cells), the mutated viruses were harvested.
Plaque assay
A 6-well plate with 6 × 105 RD cells/well was prepared
and incubated overnight at 37 °C in 5% CO2. Prior to
viral infection, the complete growth medium (DMEM
supplemented with 10% FBS) was removed and approxi-
mately 1 mL serial 10-fold dilutions of virus inoculum
was added to the cells for 1 h at room temperature with
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gentle shaking to allow for virus attachment. After 1 h
incubation, the inoculum was removed and replaced
with 2 mL of 1.2%w/v carboxylmethylcellulose. After
72 h incubation, the plaque medium was removed and
the cells were fixed with 4% formaldehyde and stained
with 0.5% crystal violet. The plaques were visible against
a white background.
Tissue Culture Infectious Dose (TCID50) assay
The EV-A71 mutant virus titers were quantitatively
determined by TCID50. TCID50 refers to the quantity of
a virus that produced a cytopathic effect in 50% of the
cultures inoculated. The TCID50 assay was carried out in
RD cells using the Reed and Muench formula [26]. A
monolayer of RD cells from a 75 cm2 tissue culture flask
was harvested after trypsinization with 1 ml of trypsin-
EDTA (Gibco, Calif., USA) and the addition of MEM
growth media to obtain a final concentration of 1 × 103
cells /μl. To assay the number of infectious virions in a
purified virus stock, serial 10-fold dilutions of the stock
virus suspension in quadruplicates, were carried out in a
96-well microtiter plate using MEM growth media as
diluent. The negative control wells contained RD cells
without any virus. The plate was incubated at 37 °C and
observed daily for CPE for up to 48 h.
Real-time RT-PCR
Total RNA was extracted from various EV-A71 mutant
strains grown in RD cells using the RNeasy extraction
kit (Qiagen, USA). Quantitative real-time PCR was per-
formed using the TouchTM Real-Time PCR Detection
System (Bio-Rad, CFX96), with 4 μl of RNA template,
10 μl of 2x SensiFAST probe No-ROX One Step Mix,
0.8uL Forward and Reverse primer (10uM), 0.2 uL probe
(10uM), 0.2 ul reverse transcriptase, and 0.4 uL RiboSafe
RNase inhibitor (BioLine, California, USA) in 20 μl of
the final reaction mixture. The reaction was performed
for one cycle at 48 °C for 10min, 95 °C for 2min,
followed by 40 cycles at 95 °C for 5s and 60 °C for 20s in
a 96-well plate. Three independent experiments were
conducted for each sample. Threshold cycle value (Cq)
data was determined using default threshold settings,
and the mean Cq was calculated from the duplicate
PCRs. A standard graph was plotted based on a series of
standard solutions.
EV-A71 VPl Immunoblot
Total cellular proteins were extracted by incubating
wild-type and EV-A71 mutant cells in lysis buffer
(20 mM Tris–HCl, pH 7.4, 1% Nonidet P-40, 137 mM
NaCl, 50 mM EDTA, protease inhibitor mixture and
1 mM phenylmethylsulfonyl fluoride). After centrifuga-
tion at 14,000 × g for 10min at 4 °C, supernatants were
transferred and mixed with an equal amount of protein
sample buffer (120 mM Tris–HCl, pH 8.0, 20% glycerol,
4% SDS, 2.5% β-mercaptoethanol and 0.05% bromophe-
nol blue). Lysates were separated by SDS-PAGE and
transferred to nitrocellulose membrane (Millipore, Calif.,
USA) that had been blocked with 5% BSA in Tris-
Buffered Saline and Tween 20 (TBST) buffer for 1h at
room temperature. The membrane was then incubated
overnight at 4 °C with anti-enterovirus VP1 monoclonal
antibody (LifeSpan BioSciences, Calif., USA) diluted in
the blocking buffer. After hybridization with primary
antibody, the membrane was washed three times with
TBST before hybridizing with anti-mouse HRP second-
ary antibody (Sigma Aldrich, St Louis, USA) diluted in
TBST. The blots were then washed three times with
TBST and detected by chemiluminescence using Image-
Quant (GE Healthcare Life Sciences, Calif., USA).
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